Table 3 Change in inflammatory mediators
From: Targeting inflammation to influence mood following spinal cord injury: a randomized clinical trial
Treatment (n = 12) | Control (n = 8) | |||||
|---|---|---|---|---|---|---|
Baseline | 1 month | 3 months | Baseline | 1 month | 3 months | |
Pro-inflammatory cytokines | ||||||
CRP (ng/ml) | 4474.7 ± 3578.9 | 3822.6 ± 3749.4 | 2865.0 ± 2684.9 | 2388.1 ± 2928.1 | 3074.0 ± 3026.4 | 2458.8 ± 3678.9 |
IL-2 (pg/ml) | 21.3 ± 51.2 | 15.1 ± 41.7 | 17.2 ± 42.1 | 1.7 ± 3.4 | 2.9 ± 3.6 | 2.3 ± 3.3 |
IL-6 (pg/ml) | 13.9 ± 28.2 | 9.2 ± 21.3 | 9.5 ± 19.3 | 9.0 ± 10.5 | 13.8 ± 21.2 | 13.5 ± 21.9 |
IL-1β (pg/ml)** | 0.9 ± 1.1 | 0.3 ± 0.3* | 0.3 ± 0.2 | 0.3 ± 0.3 | 0.4 ± 0.5 | 0.3 ± 0.2 |
TNF-α (pg/ml) | 12.5 ± 3.6 | 11.8 ± 5.5 | 11.2 ± 4.1 | 9.8 ± 3.9 | 11.3 ± 6.7 | 12.9 ± 10.3 |
IFN-γ (pg/ml)** | 52.9 ± 94.0 | 31.9 ± 57.5 | 35.0 ± 68.4 | 28.1 ± 46.8 | 48.8 ± 84.6 | 49.6 ± 95.3 |
Anti-inflammatory cytokines | ||||||
IL-4 (pg/ml) | 7.5 ± 20.8 | 12.4 ± 23.9 | 16.2 ± 38.4 | 19.8 ± 37.2 | 37.4 ± 83.8 | 23.8 ± 46.3 |
IL-10 (pg/ml) | 6.5 ± 12.9 | 11.2 ± 29.7 | 9.3 ± 22.0 | 5.9 ± 14.4 | 5.7 ± 13.7 | 6.3 ± 14.6 |
IL-1RA (pg/ml) | 33.1 ± 26.2 | 27.8 ± 18.6 | 26.3 ± 16.0 | 60.6 ± 66.6 | 77.2 ± 77.2 | 78.8 ± 105.8 |